Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 2/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12789845 | 0.83 | GRN (0.37) | CNR1CNR2HTR1AHTR7 | |
| SCHEMBL14228300 | 0.81 | GLS (0.39) | UBE2MDCUN1D1ADRA1AHRH1ADRA1B | |
| SCHEMBL14200450 | 0.79 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL20757780 | 0.78 | HTR6 (0.33) | CNR1CNR2 | |
| SCHEMBL3508345 | 0.77 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL17489165 | 0.76 | ALDH1A1 (0.34) | CNR1CNR2 | |
| SCHEMBL8270910 | 0.76 | MPO (0.39) | CNR1CNR2 | |
| SCHEMBL23329279 | 0.74 | — | — | |
| SCHEMBL12935855 | 0.74 | ADORA2A (0.36) | CNR1CNR2 | |
| SCHEMBL24246976 | 0.74 | ADRA1A (0.36) | UBE2MDCUN1D1ADRA1AHRH1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | UBE2M 2260/4885DCUN1D1 1781/4885CNR1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.